Vaccines & Disease · Hib

Haemophilus Influenzae Type B (HIB) Disease & Vaccine Information

Below are brief introductions to HIB disease and the HIB vaccine with links to more information. Scroll down for a list of QUICK FACTS that provide a summary overview of key facts for the disease and the vaccine.

The Disease

HIB: The Disease

Haemophilus influenzae type b (Hib) is a bacterial infection that can cause severe illnesses in children that include meningitis, epiglottitis, pneumonia, arthritis, and cellulitis.1 Hib meningitis, an infection of the membranes covering the brain and one of the most serious complications of Hib, may occur following an upper respiratory illness. Infection can spread from the sinuses and lungs into the bloodstream and to the brain causing meningitis.2 HIB is transmitted by direct contact with respiratory secretions and enters the body through the upper respiratory tract. In most cases, Hib can remain in the mouth and nose for up to several months, without causing illness.3 In general, HIB is considered to be minimally contagious, however, if a person has close contact to someone who is infected with or is carrying H. influenzae, transmission can occur.4

The Vaccine

HIB Vaccine

There are five Haemophilus influenzae type b vaccines available for use by the United States Food and Drug Administration (FDA) and recommended by the Centers for Disease Control (CDC). The CDC has approved Hib vaccine for use in children at 2, 4, 6 and 12-15 months of age.5

Quick Facts

Hib at a glance

Hib Quick Facts

  1. Haemophilus influenzae type b (Hib) is a bacterial infection that can cause severe illnesses in children, including meningitis, epiglottitis, pneumonia, arthritis, and cellulitis.6
  2. In general, the transmission of Hib is considered to be limited and when it occurs, it usually affects only close contacts such as household members.7 Prior to the introduction of the Hib vaccine, most children acquired natural immunity to Hib by the time they were 5 or 6 years old.8

Hib Vaccine Quick Facts

  1. All infants and children who participated in Hib vaccine pre-licensing clinical trials also received other vaccines in addition to the Hib vaccine. As a result, it is not possible to determine the specific adverse reaction to monitor for following Hib vaccination. 910111213 The administration of multiple vaccines also makes it difficult to determine the specific vaccine that might have triggered the reactions reported in both clinical studies and to VAERS.
  2. Mild side effects such as redness, warmth, or swelling where the shot was given have been reported in connection with administration of Hib vaccines.14 Systemic reactions, such as fever and irritability can also occur.15 Severe reactions involving Hib vaccination were reported during pre-licensing clinical trials and continue to be reported to the Vaccine Adverse Events Reporting System (VAERS). These include deaths, anaphylactic reactions, asthma, pneumonia, convulsions, noninfectious encephalitis, acute pancreatitis, peripheral neuropathy, Guillain-Barre syndrome, sepsis, seizures, and cerebral edema. 1617181920
References
  1. 1US Centers for Disease Control and Prevention. Types of Haemophilus influenzae Infections. Haemophilus influenzae Mar. 4, 2022.
  2. 2US National Library of Medicine MedlinePlus. Meningitis – H. influenzae. – H. influenzae. June 17, 2023.
  3. 3Communication and Education Branch, National Center for Immunization and Respiratory Diseases (NCIRD) and the Centers for Disease Control (CDC). Haemophilus influenzae type b. Haemophilus influenzae Aug. 18, 2021.
  4. 4Communication and Education Branch, National Center for Immunization and Respiratory Diseases (NCIRD) and the Centers for Disease Control (CDC). Haemophilus influenzae type b. Haemophilus influenzae Aug. 18, 2021.
  5. 5Briere EC, Rubin L, Moro PL et al. Prevention and Control of Haemophilus influenzae Type b Disease: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Feb. 28, 2014.
  6. 6US Centers for Disease Control and Prevention. Types of Haemophilus influenzae Infections. Haemophilus influenzae Mar. 4, 2022.
  7. 7Communication and Education Branch, National Center for Immunization and Respiratory Diseases (NCIRD) and the Centers for Disease Control (CDC). Haemophilus influenzae type b. Haemophilus influenzae Aug. 18, 2021.
  8. 8Communication and Education Branch, National Center for Immunization and Respiratory Diseases (NCIRD) and the Centers for Disease Control (CDC). Haemophilus influenzae type b. Haemophilus influenzae Aug. 18, 2021.
  9. 9Sanofi Pasteur, SA. Package Insert – ActHIB. U.S. Food and Drug Administration Oct. 14, 2022.
  10. 10GlaxoSmithKline Biologicals. Package Insert – Hiberix. U.S. Food and Drug Administration Oct. 3, 2019.
  11. 11Sanofi Pasteur Limited. Package Insert – Pentacel. U.S. Food and Drug Administration Oct. 24, 2022.
  12. 12Merck Sharp & Dohme Corp. Package Insert – PedvaxHIB. U.S. Food and Drug Administration Apr. 24, 2019.
  13. 13MSP Vaccine Company. Package Insert – VAXELIS. U.S. Food and Drug Administration Apr. 13, 2023.
  14. 14US Centers for Disease Control and Prevention. Haemophilus Influenzae Type b (Hib) VIS. Haemophilus Influenzae Aug. 6, 2021.
  15. 15Communication and Education Branch, National Center for Immunization and Respiratory Diseases (NCIRD) and the Centers for Disease Control (CDC). Haemophilus influenzae type b. Haemophilus influenzae Aug. 18, 2021.
  16. 16Sanofi Pasteur, SA. Package Insert – ActHIB. U.S. Food and Drug Administration Oct. 14, 2022.
  17. 17GlaxoSmithKline Biologicals. Package Insert – Hiberix. U.S. Food and Drug Administration Oct. 3, 2019.
  18. 18Merck Sharp & Dohme Corp. Package Insert – PedvaxHIB. U.S. Food and Drug Administration Apr. 24, 2019.
  19. 19Sanofi Pasteur Limited. Package Insert – Pentacel. U.S. Food and Drug Administration Oct. 14, 2022.
  20. 20MSP Vaccine Company. Package Insert – VAXELIS. U.S. Food and Drug Administration Apr. 13, 2023.
Select disease / vaccine